8-KEarnings & ResultsExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (Jul 26, 2006)

Filed July 26, 2006For Securities:ALNY

Summary

This Form 8-K filing from Alnylam Pharmaceuticals, Inc. on July 26, 2006, primarily serves to announce the company's financial results for the quarter and six-month period ended June 30, 2006. The key takeaway for investors is the release of this financial information, detailed in an accompanying press release furnished as Exhibit 99.1. While the filing itself is brief and focuses on the financial reporting, it signifies Alnylam's ongoing operational activities and transparency regarding its financial performance during that period. Investors should refer to the press release (Exhibit 99.1) for the specific details of the financial results, which would include revenue, expenses, net income or loss, and potentially updates on cash position and operational milestones. This type of report is standard for publicly traded companies and provides a snapshot of their financial health and performance.

Key Highlights

  • 1Alnylam Pharmaceuticals, Inc. announced financial results for the quarter and six months ended June 30, 2006.
  • 2The financial results were disclosed via a press release dated July 26, 2006.
  • 3The press release is furnished as Exhibit 99.1 to this Form 8-K filing.
  • 4The filing is made under Item 2.02 (Results of Operations and Financial Condition).
  • 5The information in the 8-K and the accompanying press release is furnished, not filed, for purposes of Section 18 of the Exchange Act.
  • 6The report was signed by John M. Maraganore, President and Chief Executive Officer.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially announce and provide access to Alnylam Pharmaceuticals, Inc.'s financial results for the second quarter and the first half of 2006.

The detailed financial results are contained in the press release dated July 26, 2006, which is furnished as Exhibit 99.1 to this Form 8-K filing. Investors should review this press release for specific financial data.

No, the information in this Form 8-K (including Exhibit 99.1) is furnished, not filed, for purposes of Section 18 of the Securities Exchange Act of 1934. This means it does not carry the same legal liability as 'filed' documents unless specifically incorporated by reference into another filing.

This report was signed by John M. Maraganore, who was the President and Chief Executive Officer of Alnylam Pharmaceuticals, Inc. at the time of the filing.